Compare Kimberly Clark Corp (KMB) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Kimberly Clark Corp trades at $97.99 (market cap $32.51B), while Nuvation Bio Inc. Class A Common Stock trades at $5.07 (market cap $1.74B). The key difference: Kimberly Clark Corp is far larger — about 18.7× Nuvation Bio Inc. Class A Common Stock's market cap, and Kimberly Clark Corp pays a 5.24% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| KMB | NUVB | |
|---|---|---|
Market Cap | $32.51B | $1.74B |
Volume | 6,139,913 | 9,289,619 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $9.54 |
52-Week Low | $93.05 | $3.41 |
Typical Hold Time | 93 Days | 1 Days |
Enterprise Value | $38.07B | $1.33B |
Dividend Yield | 5.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.59, up 1.15% on the day, but remains in a bearish technical trend. The stock has shown mixed earnings performance, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026, with revenue declining to $16.45 billion in 2025. The company maintains a strong dividend history, recently declaring a $1.28 payout, while navigating its pending acquisition of Kenvue and executive transitions.
KMB offers a high dividend yield near 5%, supported by 54 consecutive years of increases, but faces risks from the Kenvue integration and cash flow pressures. Analyst consensus is a 'Hold' with a $117.25 price target, suggesting moderate upside. Key risks include execution of the large acquisition and sustaining dividend payouts amid fluctuating cash flows.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
